Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
North Star in primary hypothyroidism
NCT05712421Phase 2Completed
- Sponsor
- Neuvosyn Laboratories
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of North Star in hypothyroidism (2 arms), sponsored by Neuvosyn Laboratories. Primary endpoint: Ratio of the LT4 dose to North Star dose required to maintain serum TSH levels at 30 weeks. Started Feb 2023; status: completed.
02
Drugs
North Star
03
Conditions
hypothyroidism
Beyond the preview
Go deeper on NCT05712421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712421.